Skip Navigation


International Immunology Advance Access originally published online on June 20, 2008
International Immunology 2008 20(8):1057-1066; doi:10.1093/intimm/dxn063
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/8/1057    most recent
dxn063v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Shingler, W. H.
Right arrow Articles by Harrop, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shingler, W. H.
Right arrow Articles by Harrop, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Japanese Society for Immunology. 2008. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4

William H. Shingler, Priscilla Chikoti, Susan M. Kingsman and Richard Harrop

Oxford BioMedica (UK) Ltd, Medawar Centre, Oxford Science Park, Oxford, OX4 4GA, UK

Correspondence to: W. H. Shingler; E-mail: w.shingler{at}oxfordbiomedica.co.uk

The cancer vaccine TroVax, modified vaccinia Ankara encoding the tumor-associated antigen 5T4, has been tested in phase I and II studies in colorectal cancer patients. Monitoring of 5T4-specific immune responses in patients receiving TroVax is critical since it could inform future refinements to the therapeutic or provide a surrogate marker of clinical efficacy. Tumor-specific cytotoxic T lymphocyte (CTL) are considered to be a key component of an effective anti-cancer immune response. Though numerous techniques have been employed to identify CTL epitopes, many are labor intensive, of variable reliability or biased toward common alleles such as human leukocyte antigen (HLA)-A2. A new high-throughput technique, iTopia, enables peptides to be evaluated on the basis of their physical binding properties for HLA alleles. This technique has been utilized to rapidly screen a panel of overlapping peptides, spanning the length of 5T4. Initially, peptides which bound to four class I alleles (A*0101, A*0201, A*0301 and B*0702) were identified and their physical binding characteristics assessed further by analysis of relative affinity and complex stability. 46 putative CTL epitopes have been identified which bind to at least one of the four HLA alleles. Using PBMCs from patients vaccinated with TroVax, we have used the interferon{gamma} (IFN{gamma}) ELISpot assay to validate one predicted A1 and two A2 epitopes. Conclusion: iTopia represents a rapid and high-throughput technique to identify CTL epitopes.

Keywords: 5T4, cytotoxic T-lymphocyte epitopes, TroVax, iTopia, ELISpot, immunotherapy, cancer, modified vaccinia Ankara, tumor antigen

Transmitting editor: J.P. Allison

Received 20 December 2007, accepted 22 May 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.